Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.
Experimental and Clinical Psychopharmacology · 2023-06 · 31 (3) · 593-598
DOI: 10.1037/pha0000627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Psychopharmacology, 2023-06. Verfasst von Evyn M Peters und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Saskatchewan. Hauptthemen laut MEDLINE: Ketamine, Major Depressive Disorder. Die Arbeit wurde bisher 10-mal zitiert (Crossref).
Themen: Depression
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Saskatchewan.
- College of Pharmacy and Nutrition, University of Saskatchewan.
ORCID-Profile: Evyn M Peters
Zitieren
APA
Peters, E. M., Halpape, K., Cheveldae, I., & Wanson, A. (2023). Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis. Experimental and Clinical Psychopharmacology, 31(3), 593-598. https://doi.org/10.1037/pha0000627
Vancouver
Peters EM, Halpape K, Cheveldae I, Wanson A. Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis. Experimental and Clinical Psychopharmacology. 2023;31(3):593-598. doi:10.1037/pha0000627
BibTeX
@article{Peters2023,
author = {Peters, Evyn M and Halpape, Katelyn and Cheveldae, Isaac and Wanson, Annabelle},
title = {Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis},
journal = {Experimental and Clinical Psychopharmacology},
year = {2023},
volume = {31},
number = {3},
pages = {593--598},
doi = {10.1037/pha0000627}
}
EUVIMED